Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Open-label, Randomized, Multicenter Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (BHARAT-2)

NCT07040059 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.

NCT NCT07040059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07040059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Open-label, Randomized, Multicenter Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (BHARAT-2)
Lead sponsor
Aurigene Discovery Technologies Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
March 22, 2025
Completion date
December 29, 2025
Enrollment
2 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal junction adenocarcinoma, her 2 positive gastric cancer